Zobrazeno 1 - 10
of 982
pro vyhledávání: '"amrubicin"'
Autor:
Kazutaka Mitani, Ichiro Tsuboi, Gen Tanaka, Saori Yosioka, Shuhei Yokoyama, Yusuke Kobayashi, Hirochika Nakajima, Taichi Nagami, Kohei Ogawa, Koichiro Wada
Publikováno v:
IJU Case Reports, Vol 7, Iss 2, Pp 127-130 (2024)
Introduction Small cell bladder cancer is a relatively rare tumor, representing
Externí odkaz:
https://doaj.org/article/52629ba8f6e54b98ac5e9d70fdcc7468
Autor:
Motoki Sekikawa, Haruyasu Murakami, Meiko Morita, Kosei Doshita, Keita Miura, Hiroaki Kodama, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Hirofumi Chiba, Toshiaki Takahashi
Publikováno v:
Thoracic Cancer, Vol 14, Iss 35, Pp 3475-3482 (2023)
Abstract Background Amrubicin (AMR) regimens have shown efficacy as second‐line treatment in patients with small cell lung cancer (SCLC); however, adverse events such as febrile neutropenia (FN) sometimes preclude their use. Further, the safety and
Externí odkaz:
https://doaj.org/article/4fa201b940bf4f3497e40475cb88b5de
Autor:
Yutaka Takahara, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Takashi Sakuma, Kazuaki Nishiki, Keisuke Nakase, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa, Shiro Mizuno
Publikováno v:
Thoracic Cancer, Vol 14, Iss 14, Pp 1286-1293 (2023)
Abstract Background Amrubicin (AMR) has become the standard of care for post‐relapse small cell lung cancer (SCLC). It has also been reported to achieve long‐term disease control in patients with good treatment response. However, the optimal pati
Externí odkaz:
https://doaj.org/article/99ed1c0dd4b14c28b5532ac4338190f1
Autor:
Shinya Uematsu, Satoru Kitazono, Hisashi Tanaka, Ryota Saito, Yosuke Kawashima, Fumiyoshi Ohyanagi, Takehiro Tozuka, Tsugitomi Ryosuke, Toshio Sakatani, Atsushi Horiike, Takahiro Yoshizawa, Masafumi Saiki, Yuichi Tambo, Junji Koyama, Masaki Kanazu, Keita Kudo, Yuko Tsuchiya‐Kawano, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 14, Iss 2, Pp 168-176 (2023)
Abstract Background The therapeutic efficacy of cytotoxic anticancer drugs has been reported to be enhanced after immune checkpoint inhibitors (ICI) in non–small cell lung cancer; however, it is unclear whether the same is applicable for small cell
Externí odkaz:
https://doaj.org/article/8194827c78724e359bab2959b6fa2bc1
Autor:
Kazumasa Akagi, Hirokazu Taniguchi, Minoru Fukuda, Takuya Yamazaki, Sawana Ono, Hiromi Tomono, Takayuki Suyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Yosuke Dotsu, Hiroaki Senju, Hiroshi Soda, Takashi Mizowaki, Yoshio Monzen, Takaya Ikeda, Seiji Nagashima, Yutaro Tasaki, Daisuke Nakamura, Kazutoshi Komiya, Katsumi Nakatomi, Eisuke Sasaki, Koichi Hirakawa, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 13, Iss 16, Pp 2404-2409 (2022)
Abstract Background Etoposide plus cisplatin (EP) combined with concurrent accelerated hyperfractionated thoracic radiotherapy (AHTRT) is the standard treatment strategy for unresectable limited‐disease (LD) small cell lung cancer (SCLC), which has
Externí odkaz:
https://doaj.org/article/e98bad858982435187389e1927d39f13
Autor:
Hisashi Tanaka, Yukihiro Hasegawa, Yuka Fujita, Atsushi Nakamura, Eiki Kikuchi, Yasutaka Kawai, Toshiyuki Harada, Naomi Watanabe, Hiroshi Yokouchi, Kazuhiro Usui, Ryota Saito, Hiroshi Watanabe, Tomomi Masuda, Tatsuro Fukuhara, Keita Kudo, Ryoichi Honda, Satoshi Oizimi, Makoto Maemondo, Akira Inoue, Naoto Morikawa
Publikováno v:
Thoracic Cancer, Vol 12, Iss 14, Pp 2113-2121 (2021)
Abstract Background A cisplatin plus irinotecan (CPT‐11) regimen is used for patients with extensive disease small cell lung cancer (ED‐SCLC). Amrubicin (AMR) is primarily used for relapsed SCLC. The HOT1401/NJLCG1401 trial, an open‐label rando
Externí odkaz:
https://doaj.org/article/c0e9bc75e14647f5afcebfe007cf88f5
Publikováno v:
Thoracic Cancer, Vol 12, Iss 11, Pp 1668-1672 (2021)
Abstract Background Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next‐generation a
Externí odkaz:
https://doaj.org/article/91860ec955834aad8eff9c58cb249c2c
Autor:
Takaya Ikeda, Shinnosuke Takemoto, Hiroaki Senju, Hiroshi Gyotoku, Hirokazu Taniguchi, Midori Shimada, Yosuke Dotsu, Yasuhiro Umeyama, Hiromi Tomono, Takeshi Kitazaki, Masaaki Fukuda, Hiroshi Soda, Hiroyuki Yamaguchi, Minoru Fukuda, Hiroshi Mukae
Publikováno v:
Thoracic Cancer, Vol 11, Iss 7, Pp 1972-1978 (2020)
Background The aim of this study was to assess the efficacy and safety of amrubicin for previously treated malignant pleural mesothelioma. Methods The eligibility criteria were: previously treated unresectable malignant pleural mesothelioma; performa
Externí odkaz:
https://doaj.org/article/b8beb7e2f14e48d293606d434ed3eea7
Autor:
Igawa S, Ono T, Kasajima M, Manabe H, Fukui T, Mitsufuji H, Yokoba M, Kubota M, Katagiri M, Sasaki J, Naoki K
Publikováno v:
Cancer Management and Research, Vol Volume 12, Pp 4911-4921 (2020)
Satoshi Igawa,1 Taihei Ono,1 Masashi Kasajima,1 Hideaki Manabe,1 Tomoya Fukui,1 Hisashi Mitsufuji,2 Masanori Yokoba,3 Masaru Kubota,3 Masato Katagiri,3 Jiichiro Sasaki,4 Katsuhiko Naoki1 1Department of Respiratory Medicine, Kitasato University School
Externí odkaz:
https://doaj.org/article/1cca7d0971be4b0da5da7eef4529aab6
Autor:
Reiko Sakurai, Kyoichi Kaira, Yosuke Miura, Noriaki Sunaga, Ryusei Saito, Tetsunari Oyama, Takeshi Hisada, Masanobu Yamada
Publikováno v:
Thoracic Cancer, Vol 11, Iss 2, Pp 426-435 (2020)
Abstract Background Amrubicin chemotherapy is a treatment option for patients with non‐small cell lung cancer (NSCLC) after third‐line treatment in Japan. Although topoisomerase‐II (Topo‐II), a target of amrubicin, has been reported to be a p
Externí odkaz:
https://doaj.org/article/c0b4fba13a874cfb9b70046a0f81224f